Exelixis, Inc.
EXEL · NASDAQ-GS
EXEL · NASDAQ-GS
Exelixis is a pharmaceutical and biotechnology company whose shares trade on Nasdaq under EXEL. The supplied evidence does not identify its marketed products, development pipeline, operating segments, customer groups, geographic mix, or the contribution of individual businesses to revenue. It reports FY2026 revenue of $2.3 billion and net income of $0.8 billion, compared with FY2025 revenue of $2.2 billion and net income of $0.5 billion. Thus, the evidence establishes a profitable business operating at multibillion-dollar annual revenue scale, but does not support a more detailed description of how revenue is divided among products, segments, or customers.
